Date | Time | Source | Headline | Symbol | Company |
22/10/2010 | 22:20 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
22/10/2010 | 22:18 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
22/10/2010 | 22:17 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
22/10/2010 | 22:13 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
22/10/2010 | 22:12 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
22/10/2010 | 22:11 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
15/10/2010 | 15:06 | Dow Jones News | Allos Granted Orphan Status In Europe For Lymphoma Drug | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
15/10/2010 | 14:00 | Business Wire | Allos Therapeutics' Pralatrexate Granted Orphan Medicinal Product Designation for the Treatment of Hodgkin Lymphoma by the Eu... | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
11/10/2010 | 13:19 | Dow Jones News | Allos' Pralatrexate Outperforms Tarceva In Lung-Cancer Study | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
11/10/2010 | 12:15 | Business Wire | Allos Therapeutics Announces Presentation of Favorable Survival Data from Randomized Phase 2b Study of FOLOTYN® in Patients ... | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
04/10/2010 | 15:00 | GlobeNewswire Inc. | Allos Therapeutics, Inc. (ALTH) to Ring The NASDAQ Stock Market Closing Bell | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
17/09/2010 | 21:14 | Edgar (US Regulatory) | Amended Current report filing (8-K/A) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
17/09/2010 | 21:13 | Edgar (US Regulatory) | Current report filing (8-K) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
15/09/2010 | 22:40 | Edgar (US Regulatory) | Amended Statement of Beneficial Ownership (3/A) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
15/09/2010 | 22:38 | Edgar (US Regulatory) | Amended Statement of Beneficial Ownership (3/A) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
15/09/2010 | 22:37 | Edgar (US Regulatory) | Amended Statement of Beneficial Ownership (3/A) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
15/09/2010 | 22:35 | Edgar (US Regulatory) | Amended Statement of Beneficial Ownership (3/A) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
13/09/2010 | 14:00 | Business Wire | Allos Therapeutics to Present at Upcoming Investor Conferences | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
09/09/2010 | 18:29 | Business Wire | Allos Therapeutics Announces FOLOTYN® Data Presentation at the 35th ESMO Congress | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
03/09/2010 | 22:50 | Edgar (US Regulatory) | Initial Statement of Beneficial Ownership (3) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
03/09/2010 | 22:49 | Edgar (US Regulatory) | Initial Statement of Beneficial Ownership (3) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
02/09/2010 | 21:17 | Edgar (US Regulatory) | Current report filing (8-K) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
01/09/2010 | 21:19 | Edgar (US Regulatory) | Amended Annual Report (10-K/A) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
25/08/2010 | 11:06 | Edgar (US Regulatory) | Current report filing (8-K) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
30/07/2010 | 21:17 | Edgar (US Regulatory) | Securities Registration: Employee Benefit Plan (S-8) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
28/07/2010 | 12:53 | Edgar (US Regulatory) | Quarterly Report (10-Q) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
28/07/2010 | 12:50 | Edgar (US Regulatory) | Current report filing (8-K) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
28/07/2010 | 12:30 | Business Wire | Allos Therapeutics Reports Second Quarter 2010 Financial Results | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
28/07/2010 | 12:13 | Edgar (US Regulatory) | Current report filing (8-K) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
28/07/2010 | 12:00 | Business Wire | Allos Therapeutics Announces Topline Results from Phase 2b Study of FOLOTYN in Patients with Advanced Non-Small Cell Lung Cancer | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |